Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C-Reference-Cited by-同舟云学术

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C

Published:2021-05 Issue:3 Volume:16 Page:339-355
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Yoh Kiyotaka^ORCID,Hirashima Tomonori,Saka Hideo,Kurata Takayasu,Ohe Yuichiro,Hida Toyoaki,Mellemgaard Anders,Verheijen Remy B.,Ou Xiaoling,Ahmed Ghada F.,Hayama Manabu,Sugibayashi Ko,Oxnard Geoffrey R.

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-021-00806-5.pdf

Reference35 articles.

1. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2017;35(30):3484–515. https://doi.org/10.1200/jco.2017.74.6065.

2. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv192–iv237. doi: https://doi.org/10.1093/annonc/mdy275.

3. Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(2):171–210. https://doi.org/10.1093/annonc/mdy554.

4. Wang ZF, Ren SX, Li W, Gao GH. Frequency of the acquired resistant mutation T790M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):148. https://doi.org/10.1186/s12885-018-4075-5.

5. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi: https://doi.org/10.1126/scitranslmed.3002003.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review;Clinical Lung Cancer;2024-06

2. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-11

3. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer;2023-10-27

4. Savolitinib for non-small cell lung cancer;Drugs of Today;2023-01

5. Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib;Therapeutic Advances in Medical Oncology;2023-01